The community of microbes (bacteria, fungi, viruses and their genes) living within our digestive tracts is known as the “gut microbiome,” and it can play a role in blood cancer treatment. In this 1hour presentation, you will learn:
What you eat can change your gut microbiome, which in turn can affect your response to therapy
How changing your microbiome can help fight resistance to key regulators of your immune system, and how clinical oncology practice was changed as the result of some of Dr. Routy’s and Dr. Elkrief work in this area.
Microbiomecentre clinical trials are focused on turning laboratory findings into clinical applications.
What does this area of research mean for better treatment and better quality of life for Canadians affected by a blood cancer.
Dr. Routy is a clinicianscientist and associate professor in the department of hematooncology at the CHUM (University of Montreal). Upon his recruitment to the CRCHUM in 2018 after completing his PhD with Dr. Laurence Zitvogel, Dr. Routy quickly established himself as the scientific director of the CHUM Microbiome Centre where he began his work to develop novel microbiomebased therapeutics in oncology.
His work contributed to the discovery of the gut microbiome as a novel prognostic biomarker for immune checkpoint inhibitors (ICI) in various cancers. He characterized the deleterious impact of antibioticrelated gut dysbiosis on ICI outcomes, which led to pivotal changes in clinical oncology practice. Dr. Routy has demonstrated that modulation of the microbiome by fecal microbiota transplantation, probiotics, and prebiotic supplementation had the potential to circumvent ICI resistance. His team currently leads several microbiotacentered trials in oncology ranging from phase I to phase II trials, with the aim of decreasing primary ICI resistance.
Dr. Elkrief is a medical oncologist and clinicianresearcher at CHUM/CRCHUM, where she focuses on clinical studies on the microbiome. She recently received the Cancer Research Society's Next Generation of Scientists Award and the American Society of Clinical Oncology Young Investigator Award for her research.